Croft Leominster Inc. maintained its stake in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,500 shares of the specialty pharmaceutical company’s stock at the end of the 2nd quarter. Croft Leominster Inc. owned about 0.07% of Paratek Pharmaceuticals worth $375,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Legal & General Group Plc lifted its position in Paratek Pharmaceuticals by 13.3% in the second quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after acquiring an additional 687 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Paratek Pharmaceuticals in the second quarter valued at $172,000. Citigroup Inc. lifted its position in Paratek Pharmaceuticals by 19,470.0% in the second quarter. Citigroup Inc. now owns 7,828 shares of the specialty pharmaceutical company’s stock valued at $189,000 after acquiring an additional 7,788 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Paratek Pharmaceuticals in the second quarter valued at about $200,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Paratek Pharmaceuticals in the first quarter valued at about $211,000. 82.37% of the stock is owned by hedge funds and other institutional investors.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million during the quarter, compared to the consensus estimate of $7.50 million.
PRTK has been the subject of a number of research reports. HC Wainwright upped their target price on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $50.00 target price on shares of Paratek Pharmaceuticals in a report on Wednesday, August 23rd. Raymond James Financial, Inc. reaffirmed a “strong-buy” rating and issued a $36.00 target price on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. ValuEngine cut shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 18th. Finally, BidaskClub cut shares of Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $37.44.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.